Buys
Open market- Shares
- Avg price
- Total value
Matthew R. Henn - President and Chief Scientific Officer at Seres Therapeutics, Inc.
Issuer-level insider activity
- Role
- President and Chief Scientific Officer
- Issuer ticker
- MCRB on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Matthew R. Henn in Seres Therapeutics, Inc.
Sells
Open market- Shares
- -1,504
- Avg price
- $15.59
- Total value
- -$23,448
Net
Past year- Shares
- -1,504
- Share %
- -100%
- Total value
- -$23,448
Reported holdings for Matthew R. Henn in Seres Therapeutics, Inc.
Form 4 holding
President and Chief Scientific Officer
Seres Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 7,995
- Estimated value
- $36,377
- Report date
- 17 Aug 2026
- Price
- $4.55
- Ownership
- Direct
Form 4 holding
President and Chief Scientific Officer
Seres Therapeutics, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 585
- Estimated value
- $18,996
- Report date
- 15 Aug 2026
- Price
- $0.8105
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
President and Chief Scientific Officer
Seres Therapeutics, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 25,000
- Estimated value
- Report date
- 08 Jul 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Matthew R. Henn in Seres Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.